Zobrazeno 1 - 10
of 362
pro vyhledávání: '"Henry, N"'
Autor:
Henry N. Ginsberg, Ira J. Goldberg
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 43:388-398
The positive relationship between increased levels of circulating triglycerides and cardiovascular events has been observed for decades. Driven by genetic cohort studies, inhibitors of APOC3 (apolipoprotein C3) and ANGPTL (angiopoietin-like protein)
Autor:
Rupal Trivedi-Kapoor, Kip Hardy, Michael Bacha, Ginnefer O Cox, Randall L Tackett, Henry N Young, Elisabeth L Sattler
Publikováno v:
Circulation. 147
Introduction: Despite known benefits of the DASH diet on cardiometabolic outcomes, adherence rates have been low among heart failure (HF) patients in the Southern US. Objective: To 1) use sensory evaluation methods to assess the acceptability of a ne
Autor:
Rupal Trivedi-Kapoor, Shaimaa Elshafie, Randall L Tackett, Henry N Young, Elisabeth L Sattler
Publikováno v:
Circulation. 147
Introduction: Dietary telehealth interventions were recommended for cardiovascular disease (CVD) management during the COVID-19 pandemic. Objective: To examine (1) effectiveness of dietary telehealth interventions in improving diet-related CVD risk f
Publikováno v:
European Heart Journal. 43:807-817
The past year was an exciting time for clinical lipidology when we learnt more about existing therapies as well as therapies targeting novel pathways discovered through genetic studies. LDL cholesterol remained the main target and a variety of drugs
Autor:
Jan Borén, Alberico L. Catapano, Philippe Moulin, Carlos A. Aguilar-Salinas, Anne Tybjærg-Hansen, Sander Kersten, Lale Tokgozoglu, Maurizio Averna, Chris J. Packard, Daniel Gaudet, Henry N. Ginsberg, Brian A. Ference, Gary F. Lewis, Bart Staels, Jane K Stock, Alan T. Remaley, Børge G. Nordestgaard, Alice H. Lichtenstein, M. John Chapman, Robert A. Hegele, Erik S.G. Stroes, Marja-Riitta Taskinen
Publikováno v:
European Heart Journal
European Heart Journal, 2021, pp.ehab551. ⟨10.1093/eurheartj/ehab551⟩
European Heart Journal, Oxford University Press (OUP): Policy B, 2021, pp.ehab551. ⟨10.1093/eurheartj/ehab551⟩
European Heart Journal 42 (2021) 47
European Heart Journal, 42(47), 4791-4806
Ginsberg, H N, Packard, C J, Chapman, M J, Borén, J, Aguilar-Salinas, C A, Averna, M, Ference, B A, Gaudet, D, Hegele, R A, Kersten, S, Lewis, G F, Lichtenstein, A H, Moulin, P, Nordestgaard, B G, Remaley, A T, Staels, B, Stroes, E S G, Taskinen, M-R, Tokgözoğlu, L S, Tybjaerg-Hansen, A, Stock, J K & Catapano, A L 2021, ' Triglyceride-rich lipoproteins and their remnants : Metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society ', European Heart Journal, vol. 42, no. 47, pp. 4791-4806 . https://doi.org/10.1093/eurheartj/ehab551
European Heart Journal, 2021, pp.ehab551. ⟨10.1093/eurheartj/ehab551⟩
European Heart Journal, Oxford University Press (OUP): Policy B, 2021, pp.ehab551. ⟨10.1093/eurheartj/ehab551⟩
European Heart Journal 42 (2021) 47
European Heart Journal, 42(47), 4791-4806
Ginsberg, H N, Packard, C J, Chapman, M J, Borén, J, Aguilar-Salinas, C A, Averna, M, Ference, B A, Gaudet, D, Hegele, R A, Kersten, S, Lewis, G F, Lichtenstein, A H, Moulin, P, Nordestgaard, B G, Remaley, A T, Staels, B, Stroes, E S G, Taskinen, M-R, Tokgözoğlu, L S, Tybjaerg-Hansen, A, Stock, J K & Catapano, A L 2021, ' Triglyceride-rich lipoproteins and their remnants : Metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society ', European Heart Journal, vol. 42, no. 47, pp. 4791-4806 . https://doi.org/10.1093/eurheartj/ehab551
Recent advances in human genetics, together with a large body of epidemiologic, preclinical, and clinical trial results, provide strong support for a causal association between triglycerides (TG), TG-rich lipoproteins (TRL), and TRL remnants, and inc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e78a52ae4bac2fef8e76697493cc01bd
https://hal.sorbonne-universite.fr/hal-03350304
https://hal.sorbonne-universite.fr/hal-03350304
Autor:
Stephen J. Nicholls, Gregory G. Schwartz, Kevin A. Buhr, Henry N. Ginsberg, Jan O. Johansson, Kamyar Kalantar-Zadeh, Ewelina Kulikowski, Peter P. Toth, Norman Wong, Michael Sweeney, Kausik K. Ray, the BETonMACE Investigators
Publikováno v:
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-9 (2021)
Cardiovascular diabetology, vol 20, iss 1
Cardiovascular Diabetology
Cardiovascular diabetology, vol 20, iss 1
Cardiovascular Diabetology
Background Patients with diabetes and acute coronary syndrome (ACS) are at high risk for subsequent heart failure. Apabetalone is a selective inhibitor of bromodomain and extra-terminal (BET) proteins, epigenetic regulators of gene expression. Precli
Autor:
Sibylle Hess, Charles Paulding, Catherine Boileau, M. John Chapman, Luca A. Lotta, Garen Manvelian, George D. Yancopoulos, Michael Szarek, Gonçalo R. Abecasis, Emil Hagström, Aris Baras, Sotirios Tsimikas, Robert Pordy, Henry N. Ginsberg, Amy Damask, P. Gabriel Steg, Poulabi Banerjee, Gregory G. Schwartz, Lina Badimon, John D. Overton
Publikováno v:
CIRCULATION
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Background: Alirocumab, an antibody that blocks PCSK9 (proprotein convertase subtilisin/kexin type 9), was associated with reduced major adverse cardiovascular events (MACE) and death in the ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcom
Autor:
Eric B. Rimm, Robert P. Byington, Andrew P. Levy, Martin J. Gardner, Leah E. Cahill, Steven G. Coca, Orit Lache, Thomas Ransom, Allie S. Carew, John L. Sapp, Henry N. Ginsberg
Publikováno v:
Journal of the American College of Cardiology. 75:512-521
Background Whereas there exists a direct relationship between glycated hemoglobin and cardiovascular disease (CVD), clinical trials targeting glycated hemoglobin to near-normal levels using intensive therapy have failed to prevent CVD and have even i
Autor:
Anastasiya Matveyenko, Nelsa Matienzo, Tiffany Thomas, Sekhar Ramakrishnan, Heather Seid, Henry N Ginsberg, Gissette Reyes-soffer
Publikováno v:
Circulation. 144
Introduction: ApoliproteinC3 (apoC3) is a small (~8.8kDa) protein, made in the liver. It is an inhibitor of lipoprotein lipase as well as the uptake of triglyceride (TG) rich lipoproteins and remnants by the liver. Overexpression contributes to ather
Autor:
Gissette Reyes-Soffer, Lars Berglund, Marlys L. Koschinsky, Vascular Biology, Santica M. Marcovina, P. Barton Duell, Donald M. Lloyd-Jones, Henry N. Ginsberg, Pia R. Kamstrup, Calvin Yeang, Sean P. Heffron
Publikováno v:
Arterioscler Thromb Vasc Biol
High levels of lipoprotein(a) [Lp(a)], an apoB100-containing lipoprotein, are an independent and causal risk factor for atherosclerotic cardiovascular diseases through mechanisms associated with increased atherogenesis, inflammation, and thrombosis.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40d3aac098c251445a0daadc496ded34
https://europepmc.org/articles/PMC9989949/
https://europepmc.org/articles/PMC9989949/